Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-center, Phase Ib/II Clinical Study of AK109 Combined With AK104 to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Advanced Solid Tumors

Next Previous
Trial Profile

An Open Label, Multi-center, Phase Ib/II Clinical Study of AK109 Combined With AK104 to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadonilimab (Primary) ; Pulocimab (Primary)
  • Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Akeso Biopharma

Most Recent Events

  • 12 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Apr 2027.
  • 12 Mar 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Apr 2027.
  • 23 Apr 2024 Planned End Date changed from 20 Mar 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top